Edit

CytoDyn

https://www.cytodyn.com/

Last activity: 29.02.2024

Active

Categories: BioTechDevelopmentHumanInterestITLifeLiving

CytoDyn is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses.

The Company is developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV).

The Company has one of the leading mAbs under development for HIV infection, PRO 140, which is a Late Stage 2 humanized mAb with demonstrated antiviral activity humans. PRO 140 blocks the HIV co-receptor CCR5, and clinical trial results thus far indicate that it does not affect the normal function of the cell. Results from Phase 1/1b and Phase 2a human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV.

Likes

1.64K

Followers

4.29K

Website visits

6.3K /mo.

Mentions

Location: United States, Washington, Vancouver

Employees: 11-50

Founded date: 2002

Twitter

Facebook

Investors 1

Date	Name	Website
-	Centrecour...	centrecour...

Mentions in press and media 27

Date	Title	Description
07.12.2023	CytoDyn Announces Webcast to Provide Company Update	VANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeut...
22.11.2022	CytoDyn to Host R&D Update on Wednesday, December 7, 2022	/EIN News/ -- VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for mult...
28.10.2022	CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues	/EIN News/ -- Company to complete and submit responses to FDA clinical hold Continues to study leronlimab in other HIV-related, NASH, and oncology indications Webcast to be held Monday, October 31, 2022, at 5:30 AM PT / 8:30 AM ET VANCOUVER...
28.10.2022	CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues	Company to complete and submit responses to FDA clinical hold Continues to study leronlimab in other HIV-related, NASH, and oncology indications Webcast to be held Monday, October 31, 2022, at 5:30 AM PT / 8:30 AM ET VANCOUVER, Washington, ...
19.09.2022	CytoDyn to Hold Webcast to Provide a Quarterly Company Update	VANCOUVER, Washington, Sept. 19, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeu...
19.09.2022	CytoDyn to Hold Webcast to Provide a Quarterly Company Update	/EIN News/ -- VANCOUVER, Washington, Sept. 19, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for mul...
22.06.2022	CytoDyn to Hold Webcast to Provide a Quarterly Company Update	VANCOUVER, Washington, June 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multipl...
30.03.2022	CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program	Live webcast to be held March 31 discussing announcement VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing le...
30.03.2022	CytoDyn to Hold Webcast to Provide Company Update	VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multip...
27.05.2021	Lawsuit: Investors bet big on Washington firm’s potential COVID-19 treatment as CEO cashed out	(CytoDyn Photo via investor webcast) Investors in a biotech startup developing a COVID-19 treatment claim the firm’s leaders cashed out as stock prices surged during a publicity blitz for a drug that has yet to show any value as coronavirus...
23.04.2021	CYTODYN INC. CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants	Company Achieves Total Financing in April of $57 Million VANCOUVER, Washington, April 22, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyr...
05.04.2021	CYTODYN INC. CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Accelerate Manufacturing of Leronlimab Inventory	VANCOUVER, Washington, April 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple ...
08.03.2021	CytoDyn tries to squeeze positive news out of a failed Covid-19 study — and shares take a beating	AnaptysBio shares got hammered Monday morning after the biotech conceded defeat for the first mid-stage test of its lead drug. Its antibody imsidolimab performed around as well as a placebo in fighting severe palmoplantar pustulosis, failin...
08.03.2021	Biotech IPO market looks to ramp back up as BMS partner Ikena and its immunometabolism therapies eye public offering	Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here. The IPO market has cooled off a tad from its early-year momentum, when the industry raised nearly $3 billio...
08.03.2021	Martin Shkreli faces another lawsuit, this time from insurer, alleging plans to create a monopoly for Daraprim	The notorious “Pharma Bro” Martin Shkreli prompted national outrage in 2015 when he and then-Turing Pharmaceuticals raised the price of Daraprim, the “gold standard” treatment of the parasitic infection toxoplasmos...
08.03.2021	CytoDyn tries to squeeze positive news out of a failed Covid-19 study — and shares take a beating	The “industry-wide review of accelerated approvals” that’s been making waves in the checkpoint field has reached Roche. With prodding from the FDA, the Swiss pharma giant says it’s pulling a bladder cancer indication for Tecentriq in the US...
08.03.2021	Mount Sinai leasing office space for outpatient clinics, biotech research; Zolgensma OK to be sold in UK, NICE says	A prominent New York City medical school has leased out office space in order to expand its medical research network. Mount Sinai’s Icahn School of Medicine is leasing 165,000 square feet in a building in Manhattan’s Hell’s K...
08.03.2021	Gilead's Biktarvy build its case for long-term use with 4-year data showing lasting HIV suppression	Gilead Sciences’ daily pill Biktarvy has been one of biopharma’s great success stories, riding its market leading HIV efficacy data to one of the best launches on record. Now, settling into its role as an established bran...
08.03.2021	Covid-19 roundup: Merck and Ridgeback report early data for an oral antiviral to fight the pandemic; Austria pulls a batch of AstraZeneca’s vaccine after patient death	A couple of months after scrapping its Covid-19 vaccine program, Merck has read out early data for an oral antiviral it’s developing with Ridgeback Biotherapeutics, which experts say could be the Tamiflu of coronaviru...
08.03.2021	CytoDyn tries to squeeze positive news out of a failed Covid-19 study — and shares take a beating	CytoDyn really, really wanted to put its best foot forward. So much so that, after sitting on unblinded Phase IIb/III data on leronlimab in Covid-19 for two weeks pending regulatory discussions, the biotech issued six ...
08.03.2021	Gilead's Kite keeps adding to CAR-T Yescarta's bag of tricks with FDA approval in follicular lymphoma — a first	Several months after creating the first commercial CAR-T portfolio with the FDA’s nod for Tecartus, Gilead’s Kite has racked up a sought-after new indication for its flagship cell therapy Yescarta. The FDA on Friday grant...
05.03.2021	CytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 Trial Data and Regulatory Path Forward with the U.S., U.K., Canada, Philippines and Brazil	VANCOUVER, Washington, March 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential fo...
13.07.2020	CytoDyn shares slammed as BLA filing for leronlimab in HIV hits a wall	In a press release issued in early June announcing a BLA acknowledgment letter from the FDA, CytoDyn CEO Nader Pourhassan said he is hopeful about getting a PDUFA date for its lead drug, leronlimab, on July 10. Instead, t...
01.04.2020	Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic	Alain Mérieux, founder of BioMérieux.AFP via Getty Images
20.03.2020	Charles Bancroft makes quick leap from Bristol Myers exec team to GSK; Medicxi adds two new partners to its team	Charles Bancroft → Just a few days after Bristol Myers reported that Charles Bancroft had “retired” from the executive team, he’s made a quick career shift to the board at GlaxoSmithKline. GSK reported today that Bancroft...
30.04.2019	Washington VC Watch: Pattern Computer, Chatbox, Joylux & More	Share Share on Facebook Share on Twitter LinkedIn Email Reprints Catch up on funding news from April involving technology companies based in Washington state: —Pattern Computer, a Redmond-based startup developing pattern discovery software,...
-	A top credit-risk firm says these are the 10 biotech companies most likely to go bankrupt	Credit Risk Monitor tracks the risk of bankruptcy across thousands of companies. Maksim Safaniuk/ Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Insider got exclusive access...

CytoDyn

Investors 1

Mentions in press and media 27

Reviews 0